HFS
CRSP icon

Hantz Financial Services’s CRISPR Therapeutics CRSP Stock Holding History

Hantz Financial Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76K Hold
1,400
– – ﹤0.01% 1488
2026
Q1 		$67K Buy
+1,400
New +$73.8K ﹤0.01% 1439

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Hantz Financial Services's CRSP Position: Q2 2026 in Review

Hantz Financial Services held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 1,400 shares worth $76K. The position accounts for ﹤0.01% of the portfolio, ranked #1488.

Hantz Financial Services first reported a position in CRSP in Q1 2026 and has held it in 2 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Hantz Financial Services held 1,400 shares of CRISPR Therapeutics worth $76K as of Q2 2026.
  • Hantz Financial Services left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #1488 holding.
  • Hantz Financial Services first reported a position in CRISPR Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.